Negative / Null Result ReportOpen accessMedicine· cited by 139

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model

Céline Grégoire; Caroline Ritacco; Muriel Hannon; Laurence Seidel; Loïc Delens; Ludovic Belle; Sophie Dubois; Sophie Vériter · 2019 · Frontiers in Immunology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

The finding, in one line

“However, despite promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to demonstrate their superiority over placebo in the sole phase III trial reported thus far.”

Abstract

Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft-versus-host disease (GVHD). However, despite promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to demonstrate their superiority over placebo in the sole phase III trial reported thus far. MSCs from different tissue origins display different characteristics, but their therapeutic benefits have never been directly compared in GVHD. Here, we compared the impact of BM-, umbilical cord (UC-), and adipose-tissue (AT-) derived MSCs on T-cell function in

Abstract by Céline Grégoire; Caroline Ritacco; Muriel Hannon; Laurence Seidel; Loïc Delens; Ludovic Belle; Sophie Dubois; Sophie Vériter, Frontiers in Immunology (2019) — licensed CC BY 4.0.

Read the full paper (open access)